Base de dados : MEDLINE
Pesquisa : H02.403.429.445.500 [Categoria DeCS]
Referências encontradas : 123 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 13 ir para página                         

  1 / 123 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28898986
[Au] Autor:Hess JR; Hayden BK; Cruz-Cody VG; Louzon MJ; Tuott EE; Sen NE; Gary R; Ramos PJ; Daniel-Johnson JA; Metcalf RA; Pagano MB
[Ad] Endereço:Department of Laboratory Medicine, University of Washington School of Medicine, Seattle.
[Ti] Título:Building a New Transfusion Service.
[So] Source:Am J Clin Pathol;148(2):173-178, 2017 Aug 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: For over 60 years, Harborview Medical Center (HMC) in Seattle has received its blood components and pretransfusion testing from a centralized transfusion service operated by the regional blood supplier. In 2011, a hospital-based transfusion service (HBTS) was activated. Methods: After 5 years of operation, we evaluated the effects of the HBTS by reviewing records of hospital blood use, quality system events, blood product delivery times, and costs. Furthermore, the effects of in-house expertise on laboratory medicine resident and medical laboratory scientist student training, as well as regulatory and accrediting agency concerns, were reviewed. Results: Blood use records from 2003 to 2015 demonstrated large reductions in blood component procurement, allocation, transfusion, and wastage with decreases in costs temporally related to the change in service. The turnaround time for thawed plasma for trauma patients decreased from 90 to 3 minutes. Transfusion medicine education metrics for residents and laboratory technology students improved significantly. HMC researchers brought in $2 million in transfusion research funding. Conclusions: HMC successfully transitioned to an HBTS, providing world-class primary transfusion support to a level 1 trauma center. Near-term benefits in patient care, education, and research resulted. Blood support became faster, safer, and cheaper.
[Mh] Termos MeSH primário: Transfusão de Sangue
Serviços Centralizados no Hospital/organização & administração
Medicina Transfusional/organização & administração
[Mh] Termos MeSH secundário: Serviços Centralizados no Hospital/economia
Serviços Centralizados no Hospital/métodos
Seres Humanos
Medicina Transfusional/economia
Medicina Transfusional/métodos
Washington
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170914
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqx057


  2 / 123 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28784217
[Au] Autor:Madisetty J; Wang C
[Ad] Endereço:Department of Anesthesiology and Pain Management, William P. Clements University Hospital, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, MC 9202, Dallas, TX 75390, USA.
[Ti] Título:Transfusion Medicine and Coagulation Management in Organ Transplantation.
[So] Source:Anesthesiol Clin;35(3):407-420, 2017 Sep.
[Is] ISSN:1932-2275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Organ transplantation recipients present unusual challenges with regard to blood transfusion. Although this patient population requires a larger proportion of blood product resources, liberal transfusion of allogeneic blood products can lead to a plethora of complications. Recent trends suggest that efforts to minimize bleeding, conserve products, and target transfusion to specific deficits and needs are increasingly becoming the standard practice; these must all occur with optimization of graft function and preservation in mind. With newer monitoring modalities and factor concentrates, the approach toward transfusion and bleeding in organ transplantation has rapidly improved in recent years.
[Mh] Termos MeSH primário: Transtornos da Coagulação Sanguínea/terapia
Transplante de Órgãos
Tromboelastografia/métodos
[Mh] Termos MeSH secundário: Coagulação Sanguínea
Transfusão de Sangue/utilização
Tomada de Decisões
Hemorragia/etiologia
Seres Humanos
Período Perioperatório
Medicina Transfusional
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170809
[St] Status:MEDLINE


  3 / 123 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28640786
[Au] Autor:Panigrahi AK; Yeaton-Massey A; Bakhtary S; Andrews J; Lyell DJ; Butwick AJ; Goodnough LT
[Ad] Endereço:From the Departments of *Anesthesiology, Perioperative, and Pain Medicine and Department of Pathology and †Obstetrics and Gynecology, Stanford University Medical Center, Palo Alto, California; ‡Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California; Departments of §Pathology and Pediatrics and ‖Pathology and Medicine, Stanford University Medical Center, Palo Alto, California.
[Ti] Título:A Standardized Approach for Transfusion Medicine Support in Patients With Morbidly Adherent Placenta.
[So] Source:Anesth Analg;125(2):603-608, 2017 Aug.
[Is] ISSN:1526-7598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The incidence of placenta accreta (PA) has increased from 0.8 to 3.0 in 1000 pregnancies, driven by increased rates of cesarean deliveries (32.2% in 2014) of births in the United States. The average blood loss for a delivery complicated by PA ranges from 2000 to 5000 mL, frequently requiring substantial transfusion medicine support. We report our own institutional multidisciplinary approach for managing such patients, along with transfusion medicine outcomes, in this setting over a 5-year period. METHODS: We reviewed records for patients referred to our program in placental disorders from July 1, 2009, to July 1, 2014. A placental disorders preoperative checklist was implemented to ensure optimal management of patients with peripartum hemorrhage. RESULTS: Of 136 patients whose placentas were reviewed postpartum, 21 had PA, 39 had microscopic PA, 17 had increta, 17 had percreta, and 42 had no accreta (of which 11 had placenta previa). For each subtype, the percentage of patients receiving blood products were 71% (PA), 28% (microscopic PA), 82% (increta), 82% (percreta), and 19% (no accreta). Among patients with PA or variants, 89% of patients with PA or variants underwent postpartum hysterectomy, compared to only 5% of patients with no or microscopic PA. CONCLUSIONS: Based on our experience and on the findings of our retrospective analysis, patients presenting with either antepartum radiological evidence or clinical suspicion of morbidly adherent placenta will benefit from a standardized protocol for clinical management, including transfusion medicine support. We found that massive hemorrhage is predictable when abnormal placentation is identified predelivery and that blood product support is substantial regardless of the degree of placental invasiveness. The protocol at our institution provides immediate access to sufficient volumes and types of blood products at delivery for patients at highest risk for life-threatening obstetric hemorrhage. Therefore, for patients with a diagnosis of morbidly adherent placenta scheduled for planned cesarean delivery with possible hysterectomy, a programmatic checklist that mobilizes a multidisciplinary team, including proactive transfusion medicine support, represents best practices.
[Mh] Termos MeSH primário: Transfusão de Sangue/normas
Placenta Acreta/terapia
Medicina Transfusional/métodos
[Mh] Termos MeSH secundário: Adulto
Cesárea
Parto Obstétrico/efeitos adversos
Feminino
Seres Humanos
Histerectomia
Incidência
Placenta/fisiopatologia
Placenta Acreta/diagnóstico
Placenta Acreta/epidemiologia
Placenta Prévia/diagnóstico
Placenta Prévia/epidemiologia
Hemorragia Pós-Parto/terapia
Gravidez
Estudos Retrospectivos
Medicina Transfusional/normas
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE
[do] DOI:10.1213/ANE.0000000000002050


  4 / 123 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28537975
[Au] Autor:Abuelkasem E; Hasan S; Mazzeffi MA; Planinsic RM; Sakai T; Tanaka KA
[Ad] Endereço:From the *Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and †Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland.
[Ti] Título:Reduced Requirement for Prothrombin Complex Concentrate for the Restoration of Thrombin Generation in Plasma From Liver Transplant Recipients.
[So] Source:Anesth Analg;125(2):609-615, 2017 Aug.
[Is] ISSN:1526-7598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Plasma transfusion remains the mainstay hemostatic therapy during liver transplantation (LT) in most countries. However, a large volume is required for plasma to achieve clinically relevant factor increases. Prothrombin complex concentrate (PCC) is a low-volume alternative to plasma in warfarin reversal, but its efficacy has not been well studied in LT. METHODS: Blood samples were collected from 28 LT patients at baseline (T0) and 30 minutes after graft reperfusion (T1). Factor X and antithrombin levels were measured. Ex vivo effects of PCC (0.2 and 0.4 IU/mL) and 10% volume replacement with normal plasma were compared in LT and warfarin plasma by measuring lag time, thrombin peak, and endogenous thrombin potential (ETP) using thrombin generation (TG) assay. RESULTS: Coagulation status was worsened at T1 as international normalized ratio increased from 1.7 to 3.0, and factor X was decreased from 49% to 28%. TG measurements showed normal lag time and ETP at T0 and T1, but low-normal peak at T0, and below-normal peak at T1. Both doses of PCC increased peak and ETP, while 10% volume plasma had minimal effects on TG. Thrombin inhibition appears to be very slow after adding 0.4 IU/mL of PCC in LT plasma due to low antithrombin. The same doses of PCC and plasma were insufficient for warfarin reversal. CONCLUSIONS: Reduced TG in LT can be more effectively restored by using PCC rather than plasma. The required doses of PCC for LT patients seem to be lower than warfarin reversal due to slow thrombin inhibition.
[Mh] Termos MeSH primário: Fatores de Coagulação Sanguínea/uso terapêutico
Transplante de Fígado/efeitos adversos
Trombina/fisiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Antitrombinas/sangue
Coagulação Sanguínea
Testes de Coagulação Sanguínea
Fator X/análise
Feminino
Hematócrito
Hemostasia
Hemostáticos/uso terapêutico
Seres Humanos
Coeficiente Internacional Normatizado
Masculino
Meia-Idade
Contagem de Plaquetas
Tempo de Protrombina
Fatores de Tempo
Medicina Transfusional
Transplantados
Varfarina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antithrombins); 0 (Blood Coagulation Factors); 0 (Hemostatics); 37224-63-8 (prothrombin complex concentrates); 5Q7ZVV76EI (Warfarin); 9001-29-0 (Factor X); EC 3.4.21.5 (Thrombin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE
[do] DOI:10.1213/ANE.0000000000002106


  5 / 123 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28474469
[Au] Autor:Anani WQ; Duffer K; Kaufman RM; Denomme GA
[Ad] Endereço:Diagnostic Laboratories, Medical College of Wisconsin, Milwaukee, Wisconsin.
[Ti] Título:How do I work up pretransfusion samples containing anti-CD38?
[So] Source:Transfusion;57(6):1337-1342, 2017 Jun.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Anti-CD38 is used to treat relapsed or treatment-refractory multiple myeloma. CD38 monoclonal antibodies, however, can interfere with routine blood bank serologic tests. Agglutination is observed at the indirect phase of testing as the drug binds to red blood cells (RBCs). Resolving the testing interference causes delays issuing RBC units to patients with anemia. A number of devised methods to eliminate or bypass the effects of anti-CD38 on serologic tests are in use but no panacea exists. The limitations of each method require each testing site tailor an approach to best fit their needs. We present perspectives and testing practices from a hospital transfusion medicine service and an Immunohematology Reference Laboratory managing pretransfusion samples with anti-CD38.
[Mh] Termos MeSH primário: ADP-Ribosil Ciclase 1/imunologia
Anticorpos Monoclonais/imunologia
[Mh] Termos MeSH secundário: Eritrócitos/metabolismo
Seres Humanos
Testes Sorológicos/métodos
Medicina Transfusional/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170506
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14144


  6 / 123 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28371931
[Au] Autor:Reese EM; Nelson RC; Flegel WA; Byrne KM; Booth GS
[Ad] Endereço:Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD.
[Ti] Título:Critical Value Reporting in Transfusion Medicine: A Survey of Communication Practices in US Facilities.
[So] Source:Am J Clin Pathol;147(5):492-499, 2017 May 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: While critical value procedures have been adopted in most areas of the clinical laboratory, their use in transfusion medicine has not been reviewed in detail. The results of this study present a comprehensive overview of critical value reporting and communication practices in transfusion medicine in the United States. Methods: A web-based survey was developed to collect data on the prevalence of critical value procedures and practices of communicating results. The survey was distributed via email to US hospital-based blood banks. Results: Of 123 facilities surveyed, 84 (68.3%) blood banks had a critical value procedure. From a panel of 23 common blood bank results, nine results were selected by more than 70% of facilities as either a critical value or requiring rapid communication as defined by an alternate procedure. Conclusions: There was overlap among results communicated by facilities with and without a critical value procedure. The most frequently communicated results, such as incompatible crossmatch for RBC units issued uncrossmatched, delay in finding compatible blood due to a clinically significant antibody, and transfusion reaction evaluation suggestive of a serious adverse event, addressed scenarios associated with the leading reported causes of transfusion-related fatalities.
[Mh] Termos MeSH primário: Bancos de Sangue/métodos
Comunicação
Valores Críticos Laboratoriais
Projetos de Pesquisa/normas
Medicina Transfusional/métodos
[Mh] Termos MeSH secundário: Bancos de Sangue/normas
Seres Humanos
Inquéritos e Questionários
Medicina Transfusional/normas
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqx025


  7 / 123 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28236313
[Au] Autor:Yazer MH; Lozano M; Fung M; Kutner J; Murphy MF; Oveland Apelseth T; Poglód R; Selleng K; Tinmouth A; Wendel S; Yahalom V; Biomedical Excellence for Safer Transfusion (BEST) Collaborative
[Ad] Endereço:Department of Pathology, University of Pittsburgh and the Institute for Transfusion Medicine, Pittsburgh, Pennsylvania.
[Ti] Título:An international survey on the role of the hospital transfusion committee.
[So] Source:Transfusion;57(5):1280-1287, 2017 May.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hospital transfusion committees (HTCs) can oversee all aspects of transfusion practice at a hospital. This survey sought to identify which quality variables were being reported at HTCs around the world. STUDY DESIGN AND METHODS: A working party composed of members of the Biomedical Excellence for Safer Transfusion (BEST) collaborative developed a survey of quality variables that could be potentially presented at HTC meetings. The survey was electronically sent to all BEST members who were encouraged to complete it if they were active on an HTC and to send it to other colleagues with similar experience. An expert panel was convened to determine which quality variables are the most important for review at HTC meetings. RESULTS: There were 121 respondents; the majority were from Europe (52%), Asia (19%), or North America (19%). Most respondents (68%) were at university hospitals. Of the 117 (97%) respondents with an HTC, the committee most often met quarterly (42%) and reviewed transfusion reactions (79%) and risk management-reported events (52%). The HTCs most commonly included transfusion medicine physicians, anesthesiologists, and other physicians who regularly transfuse blood products. Some of the most commonly reported quality variables included number of blood products transfused, wasted, and expired and the number of improperly labeled specimens. The expert panel analysis revealed that some variables that were deemed important were not being frequently reported at HTCs. CONCLUSION: There is variability in the variables being reported at HTCs around the world with some important variables not frequently reported.
[Mh] Termos MeSH primário: Transfusão de Sangue/normas
Comitê de Profissionais/normas
Garantia da Qualidade dos Cuidados de Saúde/métodos
Medicina Transfusional/normas
[Mh] Termos MeSH secundário: Transfusão de Sangue/utilização
Hospitais Universitários
Seres Humanos
Internacionalidade
Rotulagem de Produtos
Qualidade da Assistência à Saúde
Inquéritos e Questionários
Medicina Transfusional/recursos humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170504
[Lr] Data última revisão:
170504
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170226
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14033


  8 / 123 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28214180
[Au] Autor:Chegini A; Torab SA; Pourfatollah AA
[Ad] Endereço:Department of Immunohematology, Blood transfusion research Center, High Institute for Research and Education in Transfusion Medicine, P.O. Box: 14665-1157, Tehran, Iran. Electronic address: a.chegini@ibto.ir.
[Ti] Título:A successful experience of the Iranian blood transfusion organization in improving accessibility and affordability of plasma derived medicine.
[So] Source:Transfus Apher Sci;56(1):12-16, 2017 Feb.
[Is] ISSN:1473-0502
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Plasma is the liquid part of blood. It is estimated 21.6 million liters of plasma collect from Whole blood annually. From these plasma, 4.2 million liters transfuse, 8.1 million liters fractionate, 9.3 million liters waste. Nowadays, blood products and PDM (plasma derived medicine) consider as essential medicine in modern health care and transfusion medicine. Iranian blood transfusion organization as a non-profit organization was established in 1974 in order to centralize all blood transfusion activities from donor recruitment to distribution of blood components to hospitals. Iran is the only country in EMR region with the rate of 20-29.9 blood donations per 1000 population and reached 100% voluntary non-remunerated blood donation in 2007. RBCs and platelets demand are much more than FFPs so the IBTO was faced the surplus plasma that could cause surplus plasma wastage. Simultaneously, hospitals need more plasma derived medicine especially albumin, IVIG, factor VIII, factor IX. IBTO was faced the challenges such as Fractionators selection, Plasma volume shipment, Contract duration, Product profile, Multiple External audits, Cold chain maintenance, Transporting plasma across international borders, NAT test. To overcome plasma wastage and storage of PDM. IBTO involved toll manufacturing in 2005 and not only prevents plasma wastage but also save MOH (ministry of health) budget.
[Mh] Termos MeSH primário: Transfusão de Sangue/métodos
Plasma/metabolismo
Medicina Transfusional/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Irã (Geográfico)
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:170219
[St] Status:MEDLINE


  9 / 123 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28176343
[Au] Autor:Lin Y; Haspel RL
[Ad] Endereço:Department of Clinical Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
[Ti] Título:Transfusion medicine education for non-transfusion medicine physicians: a structured review.
[So] Source:Vox Sang;112(2):97-104, 2017 Feb.
[Is] ISSN:1423-0410
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:As transfusion is a commonly identified overused intervention, there is a clear gap between evidence-based and clinical practice. To close this gap, there is not only a need for increased transfusion medicine educational opportunities but for those using structured and proven instructional methods. Kern and colleagues have defined important steps to be considered in curricular design: general needs assessment; targeted needs assessment; goals and objectives; educational strategies; implementation; and evaluation and feedback. We use this framework to examine the current state of transfusion medicine educational initiatives for the non-transfusion medicine physician.
[Mh] Termos MeSH primário: Transfusão de Sangue
Medicina Transfusional/educação
[Mh] Termos MeSH secundário: Seres Humanos
Determinação de Necessidades de Cuidados de Saúde
Médicos/psicologia
Garantia da Qualidade dos Cuidados de Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170209
[St] Status:MEDLINE
[do] DOI:10.1111/vox.12499


  10 / 123 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28089410
[Au] Autor:Kanzler P; Mahoney A; Leitner G; Witt V; Maurer-Spurej E
[Ad] Endereço:LightIntegra Technology Inc., Vancouver, BC, Canada.
[Ti] Título:Microparticle detection to guide platelet management for the reduction of platelet refractoriness in children - A study proposal.
[So] Source:Transfus Apher Sci;56(1):39-44, 2017 Feb.
[Is] ISSN:1473-0502
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Microparticles have been shown to shed from a variety of viable cells as a consequence of inflammatory processes, activation or physical stress. Seventy to 90% of circulating microparticles are thought to be platelet-derived. The content of microparticles in blood collected from normal blood donors is highly variable and transfers into the final blood component. Elevated microparticle content (MPC) in donor blood might indicate an asymptomatic clinical condition of the donor which might affect the transfusion recipient, particularly pediatric patients. ThromboLUX is a new technology designed to routinely test biological samples for microparticle content. We compared MPC in platelet-rich plasma (PRP) of apheresis donors and the corresponding INTERCEPT-treated apheresis products (N=24). The MPCs in donor and product samples were correlated (r=0.74, P<0.001). Microparticles were significantly reduced after plasma replacement and INTERCEPT treatment. These findings are supported by phase contrast microscopy. Platelet transfusions given to patients with fever or systemic inflammation are less efficacious. In addition, transfusing heterogeneous platelets - concentrates with high MPC and activated platelets - to patients whose immune systems are activated might tip them over a threshold and cause platelet refractoriness. Restricting prophylactic platelet transfusions to homogeneous products - concentrates with resting platelets and therefore low MPC - may reduce the risk of refractoriness in cancer patients, especially children with immature immunity. To test this hypothesis we introduce an evaluation protocol for platelet management, i.e., keeping a split inventory of homogeneous and heterogeneous platelets, and using only homogeneous platelets for prophylaxis as a strategy to reduce refractoriness.
[Mh] Termos MeSH primário: Micropartículas Derivadas de Células/metabolismo
Medicina Transfusional/métodos
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Seres Humanos
Transfusão de Plaquetas/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:170117
[St] Status:MEDLINE



página 1 de 13 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde